IQ-AI Ltd's (LON:IQAI) David Smith tells Proactive London's Andrew Scott why they've put their Stonechecker software business up for sale.
The US FDA recently gave its approval for the product to be sold in the US and in that country alone there are an estimated 600,000 people each year who need treatment.
But Smith says in the big scheme of things that is considered too small compared to other the areas IQ-AI is targeting.